

Psychiatry Alerts Drug 2019 Self-Assessment Module 8: Peer Comparison

You recently participated in an ABPN-approved Self-Assessment activity relevant to your specialty and/or subspecialty. This peer comparison report provides you with feedback on your performance, relative to your peers, on the test module. In order to recognize your current knowledge base and to identify specific topics where further study may be needed, please review your answers to the following questions and compare them with those of your peers.

1) In a randomized controlled trial of patients with schizophrenia but no significant immune or inflammatory conditions, serum levels of the inflammatory marker(s) _____ were significantly higher in patients with schizophrenia than in controls.

Interleukin-1 β	0.00 %
Interleukin-6	0.00 %
Tumor necrosis factor- α	0.00 %
All of the above	100.00 %

2) Study patients treated with risperidone and 200 mg/day adjunctive minocycline demonstrated significantly greater reductions than those who received adjunctive placebo in all inflammatory markers except:

Tumor necrosis factor-α	88.00 %
Interleukin-6	0.00 %
Interleukin-1 β	12.00 %
None of the above	0.00 %

3) At 3 months, both the 100 mg/day and 200 mg/day minocycline groups showed significantly greater improvement than the placebo group in scores on the trail making test and in verbal fluency.

True	0.00 %
False	100.00 %

4) After adjustment for risperidone dosage and duration of illness, improvements in information processing speed and _____ showed a significant correlation with decreases in IL-1 β and IL-6 in the 200 mg/day minocycline group.

Working memory	0.00 %
Verbal and visual learning and memory	0.00 %
Attention and vigilance	12.00 %
All of the above	88.00 %

5) In a placebo-controlled trial in 200 reproductive-aged women with severe schizophrenia, adjunctive transdermal estradiol significantly improved scores on a range of symptom measures including the Positive and Negative Syndrome Scale (PANSS) and the Montgomery Asberg Depression Rating Scale (MADRS). However, improvements were limited to women _____ than the median age of 38 years.

Younger	0.00 %
Older	100.00 %

6) Reported adverse effects in estradiol-treated women included breast discomfort and weight gain, but long-term safety of estradiol is a concern, particularly for women with preexisting _____ and those with a past or present diagnosis of breast cancer.

Endometriosis	0.00 %
Type 2 diabetes	0.00 %
Fibromyalgia	0.00 %
Cardiovascular risks	100.00 %

7) The influence of smoking on some psychotropics (e.g., clozapine, fluvoxamine, mirtazapine, olanzapine) is well documented. Analysis of a therapeutic drug monitoring database found that despite receiving higher doses, patients who smoked cigarettes also had significantly lower serum concentrations of duloxetine than nonsmokers.

True	100.00 %
False	0.00 %

8) The results indicate that smoking status should be evaluated in patients who are prescribed duloxetine as smokers may require higher maintenance doses than nonsmokers. In addition, smoking cessation by a patient receiving a stable dose will likely be followed by a _____ increase in duloxetine concentrations.

Gradual but significant	0.00 %
Moderate but progressive	0.00 %
Rapid and considerable	100.00 %
Slow but continuous	0.00 %

9) Despite important potential advantages, very few FDA-approved drugs are available for transdermal delivery in the U.S. However, transdermal formulations of _____ are currently in development for treatment of schizophrenia.

Clozapine and olanzapine	0.00 %
Aripiprazole and asenapine	100.00 %
Cariprazine and chlorpromazine	0.00 %
Lurasidone and iloperidone	0.00 %

10) In addition to the few transdermal formulations approved for psychiatric indications (i.e., methylphenidate, selegiline, rotigotine, rivastimine), several transdermal medications including _____ are used off-label in the treatment of psychiatric disorders.

Clonidine	0.00 %
Testosterone	0.00 %
Scopolamine	0.00 %
All of the above	100.00 %

11) In a multicenter, manufacturer-sponsored, open-label study, adjunctive treatment with brexpiprazole was both safe and well tolerated for up to 6 months in patients with _____ depression.

Treatment-resistant	100.00 %
Atypical	0.00 %
Postpartum	0.00 %
Bipolar	0.00 %

12) A multicenter acute-phase 8-week controlled trial did not support the efficacy of adjunctive riluzole in patients with treatment-resistant major depression. However, in a 12-week open-label extension of the study, _____% patients who did not initially achieve response did so following extension-phase treatment.

71	33.00 %
52	0.00 %
37	0.00 %
24	67.00 %

13) Hypothermia is a rare but potentially fatal adverse effect of antipsychotic drug use. According to a review of reported cases, all of the following except _____ appear to be predisposing factors.

Presence of hypothyroidism	0.00 %
Recent drug initiation or dosage increase	0.00 %
Concurrent antidepressant treatment	100.00 %
Advanced age	0.00 %